Conclusion
The safety of SLIT is definitely proved and therefore its routine use at home is allowed. Nevertheless, the first dose should be administered under medical observation, an up-dosing schedule should be adopted and every patient treated with SLIT should be provided with an action plan for systemic and local reactions. The assessment of SLIT tolerability deserves more attention and has to be properly assessed in clinical trials and real-life studies. Further research is needed in order to evaluate the role of new strategies, such as different techniques for oral administration, in improving treatment tolerability.